支氣管擴(kuò)張劑的臨床及藥理doc-資料下載頁(yè)
2025-07-15 05:33本頁(yè)面
【正文】 心肌病、快速心律失常、對(duì)本品過(guò)敏者禁用。3．噻托溴銨（Tiotropium）：商品名為思力華（Spiriva），Boehringer生產(chǎn)。Tiotropium和Ipratropium與M受體解離半衰期不同,前者對(duì)M受體亞型具有選擇性阻斷作用，與M1和M3受體的解離時(shí)間較后者長(zhǎng)100倍，親和力較后者強(qiáng)10倍。Tiotropium的長(zhǎng)效性源于其與M3受體的緩慢解離[9]。在吸入90120分鐘后達(dá)到最大效應(yīng)，單次使用后，對(duì)肺功能的改善作用可延續(xù)24小時(shí)以上，因而僅需一日使用1次。耐受性及安全性良好。副作用主要為口干，癥狀輕微。支氣管擴(kuò)張劑在COPD和哮喘治療中普遍使用，熟悉各種擴(kuò)張劑的藥理特點(diǎn)和最新進(jìn)展，并熟練地應(yīng)用到病人身上，對(duì)呼吸科醫(yī)生是非常重要和必要的。參考文獻(xiàn)[1] Ahlquist RP. A study of adrenotropic receptors [J] Am J Physiol ,1984 ,153(2) :586600.[2] Politiek MJ ,Boorsma M,Aalben R. Comparison of formoterol and salbutamol and salmeterol in methacholineinduced severe bronchoconstrictjon. Eur Respir J ,1999 ,13(5) :988992.[3] Palmqvist M, Persson G,Lazer L ,et al . Inhaled dry powder formoterol and salmeterol in asthmatic patients :onset of action, duration of effect and potency. Eur Respir J ,1997 ,10(11) :24842489.[4] Sitar DS. Clinical pharmacokinetics of bambuterol [J ] . Clin Pharmacokinet , 1996 , 31(4) :246256.[5] Ind P W,Dal Negro R , Colman NC ,et al . Addition of salmeterol to fluticasone propionate treatment in moderatetosevere asthma [J].[6] Dennis SM, Sharp SJ , Vickers MR, Frost CD, Crompton GK, Barnes PJ , et al. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000。 355: 16759.[7] Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: casecontrol study BMJ 2005。 330:117119.[8] Pauwels RA ,Lofdahl CG,Posma DS ,et al . Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl J Med, 1997 ,337 (20) :14051411.[9] Disse B, Speck G, Rominger K, et al. Tiotropium (Spiriva?): Mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999。64:45764.
教學(xué)教案相關(guān)推薦
鄂ICP備17016276號(hào)-1